前列腺癌图像引导调强质子治疗的前瞻性PRO-Cube研究:医生报告与患者报告结局
PRO-Cube是一项前瞻性单中心注册研究,纳入155例接受每日锥形束CT引导鲁棒优化调强质子治疗的前列腺癌患者,73.6%为高危/极高危,24.5%淋巴结阳性。中位随访35.8个月,急性≥2级泌尿不良事件23.9%,无急性≥2级胃肠道不良事件,晚期≥2级泌尿和胃肠道不良事件分别为5%和4.3%,≥3级晚期不良事件<1%。患者报告结局显示治疗后早期泌尿和肠道症状加重,随后逐渐改善,与医生报告不良事件一致。
要点
- 高危/淋巴结阳性前列腺癌接受IG-IMPT后≥2级晚期泌尿和胃肠道不良事件分别仅5%和4.3%。
- 急性≥2级泌尿不良事件23.9%,主要为短暂刺激性排尿症状,无急性≥2级胃肠道不良事件。
- 患者报告结局显示治疗后早期泌尿和肠道症状加重,随后逐渐改善。
核心结论
- 尽管大分割和盆腔淋巴结照射使用频繁,IG-IMPT在高危和淋巴结阳性为主的前列腺癌队列中医生报告不良事件发生率低且患者报告结局轨迹良好。
研究设计与样本
- PRO-Cube为前瞻性单中心注册研究,纳入155例接受每日锥形束CT引导鲁棒优化调强质子治疗的连续前列腺癌患者,覆盖所有风险组,采用大分割方案伴或不伴盆腔淋巴结照射。
- 医生报告泌尿和胃肠道不良事件采用CTCAE 5.0分级,患者报告结局采用EORTC QLQ-PR25纵向分析,使用混合效应线性模型表征症状轨迹和最小临床重要差异。
主要发现
- 中位年龄70岁(IQR 62-75),73.6%为高危或极高危,24.5%淋巴结阳性,46.5%接受立体定向体部质子治疗,60%接受盆腔淋巴结照射,87.1%接受雄激素剥夺治疗。
- 中位随访35.8个月(IQR 24-52),急性≥2级泌尿不良事件23.9%,主要由短暂刺激性排尿症状驱动,无急性≥2级胃肠道不良事件。
- 累积晚期≥2级泌尿和胃肠道不良事件分别发生于5%和4.3%,≥3级晚期不良事件罕见(<1%)。
- 患者报告结局显示治疗后早期泌尿和肠道症状加重,随后随时间逐渐改善,与医生报告不良事件一致。
- 未发现患者、肿瘤或治疗相关因素与更高不良事件或不良患者报告结局相关。
关键数值与推荐
- 急性≥2级泌尿不良事件23.9%,急性≥2级胃肠道不良事件0%。
- 累积晚期≥2级泌尿不良事件5%,晚期≥2级胃肠道不良事件4.3%,≥3级晚期不良事件<1%。
临床怎么用
- IG-IMPT在大分割和盆腔淋巴结照射频繁使用的高危前列腺癌人群中显示出低不良事件率和良好患者报告结局轨迹,可作为现代调强质子治疗实践的基准。
- 结果为与当代调强放射治疗进行前瞻性比较提供了依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Multiple prospective studies have established the safety of proton therapy for localized prostate cancer. However, prospective data defining physician-reported adverse events (AEs) and patient-reported outcomes (PROs) with contemporary image guided intensity modulated proton therapy (IG-IMPT) in high-risk and node-positive disease treated with hypofractionation, including extreme hypofractionation (stereotactic body proton therapy) and pelvic nodal irradiation (PNI), remain limited. We report prospectively collected clinical outcomes from the PRO-Cube registry. METHODS AND MATERIALS: PRO-Cube is a prospective, single-center registry enrolling men with prostate cancer treated with IG-IMPT across all risk groups using hypofractionation schedules with or without PNI. This analysis included 155 consecutive patients treated definitively using daily cone beam computed tomography-guided robustly optimized intensity modulated proton therapy. Physician-reported genitourinary (GU) and gastrointestinal (GI) AEs were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, and PROs were analyzed longitudinally usingEuropean Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Prostate Cancer Module - 25 items (EORTC QLQ-PR25) with mixed-effects linear models to characterize temporal symptom trajectories and minimal clinically important difference. RESULTS: Median age was 70 years (IQR, 62-75); 73.6% had high or very high-risk disease, including 24.5% node-positive. Stereotactic body proton therapy was used in 46.5%, PNI in 60%, and androgen deprivation therapy in 87.1% of patients. With a median follow-up of 35.8 months (IQR, 24-52), acute grade ≥2 GU AEs occurred in 23.9%, driven primarily by transient irritative urinary symptoms, while no acute grade ≥2 GI AEs were observed. Cumulative late grade ≥2 GU and GI AEs were infrequent, occurring in 5% and 4.3%, respectively. Severe late AEs (grade ≥3) were rare (<1%). PRO trajectories demonstrated early posttreatment worsening in urinary and bowel symptoms, followed by gradual improvement over time, concordant with physician-reported AEs. No patient-, tumor-, or treatment-related factors were associated with higher AEs or adverse PROs. CONCLUSIONS: IG-IMPT demonstrated low rates of physician-reported AEs and favorable PRO trajectories, despite frequent use of hypofractionation and PNI in a predominantly high-risk and node-positive cohort. These findings establish a benchmark for modern intensity modulated proton therapy practice and provide a rationale for prospective comparison with contemporary intensity modulated radiation therapy.
引用
- Sundar S, Chilukuri S, Arjunan M, et al. Physician- and Patient-Reported Outcomes Following Contemporary Image Guided Intensity Modulated Proton Therapy for Prostate Cancer: Results From the Prospective PRO-Cube Study. Adv Radiat Oncol. 2026. PMID: 42657230. doi:10.1016/j.adro.2026.102096
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。